The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gleason score and the risk of cause-specific and overall mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer.
 
Laura Elizabeth Warren
No Relationships to Disclose
 
Ming-Hui Chen
No Relationships to Disclose
 
James William Denham
No Relationships to Disclose
 
Allison Steigler
No Relationships to Disclose
 
Andrew A. Renshaw
No Relationships to Disclose
 
Marian J. Loffredo
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi
 
Anthony V. D'Amico
No Relationships to Disclose